Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
A discovery in mice reveals why fasting enhances a type of breast cancer treatment — a hormone-signalling pathway and gene-expression changes have key roles. Stephen D. Hursting is in the Department ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...
Three days after releasing a large tranche of Jeffrey Epstein documents that contained few mentions of President Donald Trump ...
Ernexa is advancing a best-in-class approach using synthetic, allogeneic iMSCs to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The Company continues to ...
In August, the corpses of four men were found along the banks of the river in Val-de-Marne, just outside Paris. Le Monde ...
Analyzing stochastic cell-to-cell variability can potentially reveal causal interactions in gene regulatory networks.
The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...
PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...
The European Commission on Tuesday made public proposals that reverse an effective ban on sales of new internal combustion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback